To register online and poster submission, visit the activity website at BaylorCME.ORG/CME/1576

For more information, please contact Christina Velasquez at cguerrer@bcm.edu

DAN L DUNCANCOMPREHENSIVEC A N C ER C ENTER

1ST ANNUALHEMATOLOGIC MALIGNANCIES

SYMPOSIUM

SATURDAY, NOV. 3, 2018BCM MAIN - CULLEN AUDITORIUM & RAYZOR LOUNGE

PM Poster Session • 12:00pm–12:45pm Presentations • 8:00am–4:00pm

BAYLOR ST. LUKE’S & DAN L DUNCAN COMPREHENSIVE CANCER CENTER

Provided by

PLANNING COMMITTEEGustavo Rivero, MD

Martha P. Mims, MD PhD

Charles Kent Osborne, MD

KEY LECTURERS Clara D. Bloomfield, MD

The Ohio State University Comprehensive Cancer Center

Hetty Carraway, MD, MBA, FACPCleveland Clinic Lerner College of Medicine of Case

Western Reserve University

Cynthia Dunbar, MDNational Heart, Lung, and Blood Institute

Arnold Ganser, MDHannover Medical School

Guillermo Garcia-Manero, MDThe University of Texas MD Anderson Cancer Center

Sergio Giralt, MD, FACPMemorial Sloan Kettering Cancer Center

Mark Levis, MD, PhDThe Sidney Kimmel Comprehensive Cancer Center, John Hopkins University

Guido Marcucci, MDCity of Hope and Beckman Research Center

Eric Padron, MDMoffitt Cancer Center

Rachel R. Rau, MDTexas Childrens Hospital, Baylor College of Medicine

Phillip Scheinberg, MDHospital A Beneficência Portuguesa São Paulo

David P Steensma, MD FACPDana-Farber Cancer Institute

Eytan M. Stein, MDMemorial Sloan-Kettering Cancer Center

Roland B. Walter, MD PhD MSFred Hutchinson Cancer Research Center

NEEDSThis inaugural symposium will bring together recognized national and international speakers to address recent advances in diagnosis and treatment of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). In recent years, the discovery of clonal hematopoiesis of indeterminate potential (CHIP) greatly impacted scientific view of leukemogenesis. How CHIP configurates risk for clonal myeloid neo-plasms in adult and elderly patients became an attractive and urgent research entity. We are starting to observe progress, but undoubtedly, significant work is still needed. Among clonal myeloid disorders, MDS is mostly observed in elderly patients and confers variable risk for AML transformation. While low-risk MDS patients are treated with growth factors and lenalidomide, high-risk MDS patients deemed unsuitable for allogenic bone marrow transplantation are treated with hypomethylating agents. A significant number of cases exhibit primary refractory disease or relapse soon after achieving initial response highlighting that novel therapy design is urgently needed. In adult patients initially diagnosed with MDS who evolve to AML, or present with de novo disease, significant progress has been made in understanding AML pathogene-sis. Cytarabine (Ara-C) plus anthracycline [7+3 regimen] followed by high-dose cytarabine (HIDAC) and/or stem cell transplantation [in selected intermediate and suitable unfavorable risk patients] is still consid-ered standard of care. However, differential outcome is frequently observed, with large number of cases exhibiting inferior survival. AML molecular heterogeneity explains, at least in part, lack of uniform therapy response. 2017 and early 2018 represents historical momentum gained by FDA approval of 5 new AML drugs. Among them, three drugs to target leukemia “gene addiction” [i.e. FLT3 ITD, FLT3 TKD, IDH1 and IDH2]; one antibody-drug-conjugate directed against CD33 and liposomal cytarabine/anthracycline for treatment of therapy-related and myelodysplasia-related changes AML. During our symposium, we will emphasize the need for physicians to combine up-to-date knowledge and technology to efficiently identify “actionable targets” for treatment of AML and MDS patients. Additionally, novel MDS and AML pathogene-sis insight could provide opportunity for clinical trial design.

TARGET AUDIENCEThis course is designed for practicing hematologist, oncologist, physician assistants, basic scientist, nurse practitioners, hematology and oncology fellows, residents and students.

EDUCATIONAL OBJECTIVEAt the conclusion of the activity, participants should be able to:

• Discuss applicability of new FDA agents in targeted therapy for AML and MDS.

• Describe current concepts for risk stratification of AML.

• Describe the correlation between clonal hematopoiesis and risk ofdeveloping MDS, AML, and cardiovascular disease.

• Execute better treatment decisions for patients presenting withAML or MDS.

EDUCATIONAL METHODS Lectures, panel discussions, case studies, audience response system, as well as questions and answer session.

EVALUATIONEvaluation by questionnaire will address program content, presentation, and possible bias.

ACCREDITATION/CREDIT DESIGNATIONBaylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cizik School of Nursing UTHealth is an approved provider of continuing nursing education by the Texas Nurses Association - Approver, an accredited approver with distinction by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity provides 5.75 contact hours on Nursing Continuing Education.

DISCLOSUREIn order to meet the requirements of the Accreditation Council for Continuing Medical Education (ACCME) it is the policy of Baylor College of Medicine that all individuals who are in a position to control the content of a CME course (course director, planning committee members, and faculty) disclose relevant financial relationships with commercial interests. All identified conflicts of interest are managed to help ensure that the educational material is scientifically based, accurate, and objectively presented. Specific disclosure will be made to the participants prior to the educational course.

Audio or videotaping is prohibited without written permission from the Activity Director and the Office of Continuing Medical Education, Baylor College of Medicine, Houston, Texas.

CANCELLATION/REFUND POLICY Requests for registration refunds must be in writing and received by the OCME at least 10 business days before the activity begins. The date the request is received by the OCME will be considered the cancellation date. Requests received after the refund deadline will not be processed. Cancellations are subject to a $50 administrative fee deducted from the registration fee paid to cover guarantees and other expenses. Requests should be mailed to the OCME or faxed to 713.798.7955.

The OCME reserves the right to cancel activities, not less than 10 business days before the scheduled date, if extenuating circumstances make it necessary. Registrants will be notified at the contact number indicated on the registration form followed by written notification. If an activity is cancelled, OCME’s liability is limited to the registration fee paid. Note: If payment is made by check, a social security number is required to process the refund.

To register online, visit the activity website at BaylorCME.org/CME/1576

PRELIMINARY SCHEDULE • SATURDAY, NOVEMBER 3, 2018

Morning Sessions

8:00am-8:05am Welcome by symposium chairs–

Martha P. Mims, MD PhD; Kent Osborne, MD; Gustavo Rivero, MD

Clonal hematopoiesis and myelodysplasia

8:05am-8:25am Chipping to understand the origin of hematologic malignancies and atherosclerosis

Speaker: David P Steensma, MD FACPDana-Farber Cancer Institute

8:30am-8:50am Hemopoeitic stem cell and aging

Speaker: Cynthia Dunbar, MDNational Heart, Lung, and Blood Institute

8:55am- 9:15am MDS/AML epigenome

Speaker: Rachel Rau, MDTexas Children’s Hospital, Baylor College of Medicine

9:20am-9:40am Myelodysplasia vs Aplastic Anemia or both?

Speaker: Phillip Scheinberg, MDHospital A Beneficência Portuguesa de São Paulo

9:45am-10:05am Case based lecture on- Novel therapies for low–risk MDS

Speaker: Guillermo Garcia Manero, MDThe University of Texas MD Anderson Cancer Center

10:10am-10:30am Case based lecture on novel therapies for high–risk MDS

Speaker: Eric Padron, MDMoffitt Cancer Center

Acute myelogenous Leukemia

10:35am-11:00am ELN risk stratification and novel biomarkers for AML prognostication –

Speaker: Clara D. Bloomfield, MD The Ohio State University Comprehensive Cancer Center

11:05am-11:25am Treatment of favorable ELN risk

Speaker: Hetty Carraway, MD, MBA, FACPCleveland Clinic Lerner College of Medicine of Case Western Reserve University

11:30am-11:50am Treatment of unfavorable ENL risk

Speaker: Arnold Ganser, MD Hannover Medical School

BREAK • POSTER EXHIBITS • POSTER PRESENTATION

Afternoon Sessions

12:45pm-1:15pm FLT3 inhibition- harnessing the proliferative addiction

Speaker: Mark Levis, MD, PhD, The Sidney Kimmel Comprehensive Cancer Center-Johns Hopkins University

1:20pm-1:50pm Where are we going with IDH1/2 differentiating therapy?

Speaker: Eytan M. Stein, MDMemorial Sloan-Kettering Cancer Center

1:55pm-2:15pm Monoclonal antibodies- what is the place in management of AML?

Speaker: Roland B. Walter, MD PhD MSFred Hutchinson Cancer Research Center

2:20pm-2:40pm Treatment-related AML

Speaker: Guido Marcucci, MDCity of Hope and Beckman Research Center

2:45pm-3:15pm Panel discussion

Guido Marcucci, MDCity of Hope and Beckman Research Center

Eytan M. Stein, MDMemorial Sloan-Kettering Cancer Center

Hetty Carraway, MD, MBA, FACP Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center

3:20pm-3:50pm How can we optimize post bone marrow transplantation in AML?

Speaker: Sergio A. Giralt, MD, FACP Memorial Sloan-Kettering Cancer Center

3:50pm-4:00pm Closing remarks • abstract winners’ announcement